Oncolin Therapeutics

Oncolin Therapeutics was a biotechnology company dedicated to developing first-in-class small molecule inhibitors for the treatment of various cancers. The company's research platform focused on targeting the Hypoxia-Inducible Factor 1 (HIF-1) pathway, a key regulator of tumor adaptation to hypoxic environments. Its lead development candidate, ONC-101, was designed to inhibit HIF-1 alpha to suppress tumor growth and angiogenesis. Founded by Dr. William G. Rice, the company sought to leverage novel insights into tumor biology to create effective oncology treatments. The company operated primarily in the early 2000s and focused on the intersection of medicinal chemistry and molecular oncology. Oncolin Therapeutics is currently considered inactive, with its core leadership and intellectual focus transitioning into subsequent ventures in the biopharmaceutical sector.